Podcasts about early detection

EPISODE NOTESJamie and Matt open the episode with lighthearted holiday banter and personal Christmas traditions.This 99th episode marks a milestone far beyond the average podcast lifespan of seven episodes.Jamie introduces the shift from typical healthcare culture/policy topics to a deeply personal conversation about patient experience from Matt's perspective.Matt admits he's more nervous for this episode than almost any other—because it's personal.The conversation acknowledges the hardship of 2024–2025 for both hosts' families.Matt walks through how a wellness check and PSA screening unexpectedly detected something abnormal.An MRI experience becomes meaningful thanks to a tech who sensed his anxiety and used music to calm him—highlighting how small patient-experience moments matter.The MRI revealed something suspicious, leading to a biopsy.Matt received his cancer diagnosis alone in a conference center during a professional event—an emotionally jarring moment.He immediately sought clarity and support from a physician colleague, who helped him interpret the results.Matt reflects on the shock of seeing “prostate cancer” in writing and how it triggered grief-like emotions.He emphasizes the importance of asking for results early so patients can process before appointments.His urologist spent over an hour walking through options—an impactful example of patient-centered communication.

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sean Cassidy, CEO and Co-Founder of Lucem Health, is applying AI to identify patients at high risk of undiagnosed conditions like cancer and diabetes.  The goal is to facilitate earlier diagnosis and treatment by flagging patients that need screening based on the AI plaform's ability to analyze EHR data and demographics of diverse patient populations to ensure broad scalability. This technology was designed to integrate into existing clinical workflows for established screening procedures rather than making direct treatment recommendations.  Sean explains, "The origin of the company, the idea for the company, originated within Mayo Clinic in about 2020. Mayo Clinic has faced a challenge, and I think sometimes continues to face a challenge that a lot of researchers in AI have faced, which is how do you get promising AI in a clinical context from the so-called bench to the bedside? How do you get it from the lab into clinical practice? And what they realized was that while the data science and the AI part of it is really interesting, what was needed was scaffolding around the AI to facilitate integration with data and integration with workflows, a measurement and monitoring system, and so on and so forth." "We are trying to facilitate, and you're going to see us begin to expand the aperture, if you like, or open the aperture of how we position the company. Because as we've gone on, we have realized that the opportunity here is to actually help healthcare provider organizations, health systems, and so on, create really high-impact care delivery programs that have at their core or feature at their core earlier diagnosis, accelerated treatment, earlier treatment and therefore better outcomes for patients and hopefully even saved lives. So that's the generic approach that we take."  #LucemHealth #AIinHealthcare #HealthcareAI  #HealthTech #EarlyDiseaseDetection lucemhealth.com Download the transcript here

Sean Cassidy, CEO and Co-Founder of Lucem Health, is applying AI to identify patients at high risk of undiagnosed conditions like cancer and diabetes.  The goal is to facilitate earlier diagnosis and treatment by flagging patients that need screening based on the AI plaform's ability to analyze EHR data and demographics of diverse patient populations to ensure broad scalability. This technology was designed to integrate into existing clinical workflows for established screening procedures rather than making direct treatment recommendations.  Sean explains, "The origin of the company, the idea for the company, originated within Mayo Clinic in about 2020. Mayo Clinic has faced a challenge, and I think sometimes continues to face a challenge that a lot of researchers in AI have faced, which is how do you get promising AI in a clinical context from the so-called bench to the bedside? How do you get it from the lab into clinical practice? And what they realized was that while the data science and the AI part of it is really interesting, what was needed was scaffolding around the AI to facilitate integration with data and integration with workflows, a measurement and monitoring system, and so on and so forth." "We are trying to facilitate, and you're going to see us begin to expand the aperture, if you like, or open the aperture of how we position the company. Because as we've gone on, we have realized that the opportunity here is to actually help healthcare provider organizations, health systems, and so on, create really high-impact care delivery programs that have at their core or feature at their core earlier diagnosis, accelerated treatment, earlier treatment and therefore better outcomes for patients and hopefully even saved lives. So that's the generic approach that we take."  #LucemHealth #AIinHealthcare #HealthcareAI  #HealthTech #EarlyDiseaseDetection lucemhealth.com Listen to the podcast here

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Early cancer detection significantly increases survival rates and reduces the overall health and financial burden. In this episode, Trudy McKanna, Senior Field Medical Director for GRAIL, discusses how Galleri multi-cancer early detection technology is transforming screening by identifying signals for more than 50 cancers through a simple blood draw. She explains how methylation patterns, cell-free DNA, and machine learning allow clinicians to pinpoint potential cancer origins before symptoms appear. Trudy shares data showing that adding this test to standard screening detects seven times more cancers, with over half found at early stages, while maintaining a remarkably low false-positive rate. She also highlights its impact on underserved communities, population health scalability, and the importance of rigorous clinical validation.  Tune in and discover how early detection can transform cancer outcomes! Resources Connect with and follow Trudy McKanna on LinkedIn. Follow GRAIL on LinkedIn and visit their website! Learn more about Galleri here.

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of The Dr. Hyman Show, I'm joined by Maria Menounos, journalist, actor, and founder of Heal Squad, to explore what it truly means to take ownership of your health. After years of pushing through nonstop stress and serious health challenges, Maria discovered that real healing starts with mindset, community, and self-advocacy. Watch the full conversation on YouTube or listen wherever you get your podcasts. We discuss: • How you can recognize early warning signs and take action before they become bigger health issues • Why small rituals can make wellness social, joyful, and sustainable • Tools to build a team that truly supports your healing • Simple mindset practices to reframe fear and find strength through uncertainty • The daily choices that help you move from survival mode to genuine healing Maria's story is a reminder to us all that healing starts with paying attention to your body, your thoughts and the community you choose to surround yourself with. View Show Notes From This EpisodeGet Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Pique, Timeline, Function Health, Big Bold Health, Paleovalley and BON CHARGE. Receive 20% off FOR LIFE + a free Starter Kit with a rechargeable frother and glass beaker at Piquelife com/Hyman. Support essential mitochondrial health and save 20% on Mitopure. Visit timeline.com/drhyman to get 20% off today. Join today at FunctionHealth.com/Mark and use code MARK2026 to get $50 OFF toward your membership. Get 20% off HTB Immune Energy Chews at bigboldhealth.com and use code DRMARK20. Get nutrient-dense, whole foods. Head to paleovalley.com/hyman for 15% off your first purchase. This holiday season get 25% off until December 31st. Head to boncharge.com to receive this offer today! (0:00) Introduction and Maria Menounous's health journey (2:07) Dr. Hyman and Maria Menounous on overcoming health challenges (7:21) The impact of toxic work environments and IVF risks (12:01) Autoimmune issues, cancer, and the importance of early screening (17:03) Mindset and tools for handling life's challenges (26:11) Discussing poor nutrition in hospitals and the importance of a health toolkit (30:51) The role of community in healing and introduction to Heal Squad (38:58) The significance of self-care and Dr. Hyman's personal health struggle (43:31) How facing adversity improves medical practice and the science of health (49:02) Caring for caregivers and the value of a health collaborator (53:45) Maria's daily routine, emotional, and spiritual health strategies (1:02:18) The influence of thoughts on biology and prayer (1:06:58) Maria Menounos's work with Heal Squad and her WWE career (1:07:28) Closing remarks and call to action (1:08:10) Disclaimer and gratitude to sponsors

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breast cancer often surfaces in the moments people don't talk about—appointments pushed months out, mixed messages from providers, and the quiet fear that something serious might be brushed aside.In this episode, Michael Desrosiers sits down with flight attendants Kimberly Burckhalter and Derrian Aversa, whose diagnoses are decades apart yet shaped by the same need to push for answers. Kim recalls finding a lump in her early thirties and refusing to accept reassurances that didn't feel right. Derrian explains how today's advanced treatments still sit behind layers of scheduling delays, limited staffing, and constant follow-up calls.Their conversation asks the harder questions. Why do some patients move quickly through care while others face roadblocks at every step? How much do geography, staffing shortages, and insurance policies determine the path long before treatment begins? And what kind of support truly helps when fear takes over and details become hard to process?Together, they offer a clear, compassionate reminder: trust what your body is telling you, speak up early, and keep people close who help you stay steady when the system makes everything harder than it should be.Episode Breakdown:00:00 Breast Cancer Awareness01:00 Early Detection and Kim's Diagnosis04:16 Derrian's Delayed Care and HER2-Positive Results09:48 Why Support Systems Matter10:37 Flight Attendant Risk Factors15:16 Healthcare Delays and Systemic Barriers20:36 Insurance Challenges and Access to Treatment30:32 Advances in Breast Cancer Treatment35:00 Self-Advocacy and Early ActionLinksVisit the Cuckoo4Politics websiteFollow Cuckoo4Politics on InstagramFollow Cuckoo4Politics on FacebookFollow Cuckoo4Politics on TikTokFollow Cuckoo4Politics on BlueskyPodcast production and show notes provided by HiveCast.fm

Learn more about Brodie's Research Database & AI Assistant

Top Stories for November 29th Publish Date: November 29th PRE-ROLL: SUGAR HILL ICE SKATING From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Saturday, November 29th and Happy Birthday to Vin Scully I’m Peyton Spurlock and here are your top stories presented by Gwinnett KIA Mall of Georgia. Piedmont Oncology Opens Early Detection Pancreatic Cancer Clinic, First of Its Kind in Georgia You can now use a digital driver’s license to buy beer, cigarettes in Georgia Musical events, attractions to get into the magical spirit of the holiday season All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: Kia Mall of Georgia STORY 1: Piedmont Oncology Opens Early Detection Pancreatic Cancer Clinic, First of Its Kind in Georgia Piedmont Oncology just opened Georgia’s first Early Detection Pancreatic Cancer Clinic, and honestly, it’s a big deal. Pancreatic cancer is brutal—13% five-year survival rate, no screening test, vague symptoms that sneak up on you. But this clinic? It’s here to change that. Dr. Andrew Page, the clinic’s medical director, says early detection is everything. “Education about risk factors is critical,” he explained. The clinic will focus on genetic counseling, research collaborations with NIH and Mayo Clinic, and, hopefully, developing a much-needed screening test. None of this would’ve happened without donors like Purple Pansies. Their support is saving lives. STORY 2: You can now use a digital driver’s license to buy beer, cigarettes in Georgia Big news for Georgians: you can now use a digital driver’s license to buy alcohol, tobacco, and other age-restricted items. Yep, your phone just got even more useful. The Georgia Department of Driver Services (DDS) announced the update Monday, calling it a “major step forward” in modernizing IDs. But here’s the catch: it’s up to individual businesses to accept them. No guarantees. Oh, and don’t try using a screenshot—doesn’t count. Retailers need a special mDL reader to scan the license, and staff still have to verify your age. Progress? Sure. Perfect? Not quite yet. STORY 3: Musical events, attractions to get into the magical spirit of the holiday season It’s that time again—holiday magic is everywhere, and Atlanta’s got no shortage of ways to celebrate. From concerts to tree lightings, here’s what’s happening: Holiday Shows at the FOX Theatre: Lauren Daigle’s Behold Christmas Tour (Dec. 4): Grammy-winning magic. Christmas Together (Dec. 6): Amy Grant, Cece Winans, and Michael W. Smith. A Drummer Boy Christmas (Dec. 8): for King + Country’s festive storytelling. Elf the Musical (Dec. 16–20): Buddy’s heartwarming journey. Nutcracker! Magical Christmas Ballet (Dec. 23–24): Ballet meets acrobatics. Festive Attractions: Stone Mountain’s Flight to the North Pole (Nov. 8–Jan. 4): Help Santa save Christmas. Garden of Lights (Nov. 15–Jan. 11): Stroll through dazzling displays. Georgia Aquarium Holidays (Nov. 14–Jan. 2): Twinkling lights, Santa, and sea life. Don’t miss these great events! We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: Ingles Markets - DTL HOLIDAY STORY 4: Student loan change could drain nurse pipeline, Ga. dean warns Nursing is no longer considered a “professional degree” by the U.S. Department of Education, and nurses are, understandably, furious. The change, tied to the “One Big Beautiful Bill”, means nursing students can’t access the $200,000 loan cap reserved for professional programs. Instead, they’re stuck with a $100,000 limit—less than what many need to cover tuition. Linda McCauley, dean of Emory’s Nursing School, didn’t hold back: “In a time when we desperately need more nurses, why make it harder? It feels like they didn’t think this through.” The fallout? Fewer nurses, more debt, and a lot of frustration. STORY 5: Flight delays: Here are your rights when flying over the holidays in 2025 Stuck at the airport? Here’s a tip: if your flight’s delayed more than three hours (domestic) or six hours (international), you’ve got rights. Travel expert Katy Nastro says airlines must offer a refund or rebook you—your choice. But here’s the catch: no double-dipping. You can’t get both. And meal vouchers? Only if the delay’s the airline’s fault, like staffing or mechanical issues. Hotels? Depends on the airline. The Department of Transportation even published a guide for what airlines owe you. Pro tip: screenshots of your license don’t count for ID. Break 3: BUFORD HOLIDAY FESTIVAL STORY 6: Forsyth school board approves use of same alarm system in place at Apalachee High School Forsyth County schools are stepping up safety with a $2.4 million Centegix alarm system, approved by the Board of Education this week. You’ve probably heard of these “panic alarms”—they’re the same system credited with the quick response during the tragic Apalachee High School shooting last year. Teachers and staff wear a button they can press in emergencies, instantly alerting law enforcement without fumbling for a phone. The system also includes color-coded strobe lights for visual alerts, ensuring ADA compliance. The first year’s cost? $420,000, with the rest spread over five years. Safety, it seems, is getting an upgrade. STORY 7: Recall alert: Honda recalls 256K vehicles for loss of power software error Honda’s recalling over 256,000 vehicles—specifically 2023–2025 Accord Hybrids—because of a software glitch that could cause the car to lose power mid-drive. Not ideal, right? The issue? The integrated control module’s CPU might reset itself while you’re cruising along. Dealers will fix it for free, though, so there’s that. Honda says owners will get a heads-up by mail starting Jan. 5, but if you’re the impatient type (or just worried), you can call them at 888-234-2138. Oh, and if you’re curious, the recall number is TN2. Stay safe out there! We’ll have closing comments after this Break 4: THE SUGAR HILL HOLIDAY Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com www.kiamallofga.com 2025 Buford Holiday Festival & Parade All-In-One Flyer Holiday Celebration 2025 – City of Sugar Hill Ice Rink – Downtown Sugar Hill NewsPodcast, CurrentEvents, TopHeadlines, BreakingNews, PodcastDiscussion, PodcastNews, InDepthAnalysis, NewsAnalysis, PodcastTrending, WorldNews, LocalNews, GlobalNews, PodcastInsights, NewsBrief, PodcastUpdate, NewsRoundup, WeeklyNews, DailyNews, PodcastInterviews, HotTopics, PodcastOpinions, InvestigativeJournalism, BehindTheHeadlines, PodcastMedia, NewsStories, PodcastReports, JournalismMatters, PodcastPerspectives, NewsCommentary, PodcastListeners, NewsPodcastCommunity, NewsSource, PodcastCuration, WorldAffairs, PodcastUpdates, AudioNews, PodcastJournalism, EmergingStories, NewsFlash, PodcastConversations See omnystudio.com/listener for privacy information.

About Trudy McKanna:Trudy McKanna is an accomplished medical affairs leader with extensive experience across medical education, field medical strategy, and people management. Currently serving as Senior Field Medical Director at GRAIL, she brings more than two decades of expertise spanning oncology, organ health, genetics, and medical ethics. Prior to GRAIL, she spent nine years at Natera in progressively senior roles, including Senior Director of Medical Affairs for Organ Health, where she led medical strategy, built and managed high-performing teams, and shaped national KOL engagement efforts across transplant and renal genetics. Her background includes over a decade as a genetic counselor and supervisor at Spectrum Health, leadership roles in professional organizations such as the Michigan Association of Genetic Counselors, and academic appointments with Michigan State University. As co-founder and vice president of the Rockford Food Allergy Network, she also helped strengthen community education and advocacy around food allergy awareness. Trudy holds a Master of Science in Genetic Counseling from the University of Michigan and a Bachelor of Science in Biology/Biochemistry from Hope College.Things You'll Learn:Early detection significantly changes survival outcomes; identifying cancer before it metastasizes can quadruple five-year survival rates.Multi-cancer early detection utilizes cell-free DNA and methylation patterns to detect signals from over 50 cancers with a simple blood draw.Adding this test to standard screening results in seven times more cancers being found, with over half detected at early stages.The false-positive rate is exceptionally low at 0.4%, making it viable for population-scale screening.Access and equity improve significantly when screening can be conducted in primary care settings, mobile units, employer sites, and underserved communities.Resources:Connect with and follow Trudy McKanna on LinkedIn.Follow GRAIL on LinkedIn and visit their website.Learn more about Galleri here.

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A bustling port fuels more than trade. It sustains everyday life in ways most never see. Garret Berg and Jessica Mendoza from Port Houston share how the Houston Ship Channel keeps the city moving, from the clothes we wear to the cars we drive. Through their work, they connect communities, support local nonprofits like The Rose, and create opportunities for families across the region. Beneath the surface, the port’s reach extends far beyond the water. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What is Port Houston and what does it do? What kinds of cargo come through Port Houston? What is “break bulk” cargo? What roles do Jessica and Garrett have at Port Houston, and what are their backgrounds? What does the term “maritime industry” mean in the context of Port Houston? How does Port Houston engage with the community? Why did Port Houston choose to fund The Rose? What is Port Houston’s history and significance to Houston’s development? What opportunities does Port Houston offer for public engagement, like tours? What types of programs does Port Houston have beyond shipping, particularly regarding workforce and small businesses? How does Port Houston’s grants committee work when selecting nonprofits for funding? What has been the personal impact of breast cancer among the guests? What are some challenges in community outreach for Port Houston? How do the guests’ family and parenthood perspectives affect their work and values? Timestamped Overview 00:00 Houston Port Communications Journey 03:57 Understanding Maritime's Economic Impact 09:02 Early Detection and Survival Stories 12:33 Unique Free Port Houston Tour 16:21 Connecting Through Community Engagement 18:59 Community Needs and Funding Challenges 20:18 Raising Awareness About Houston Port 25:13 Passion and Kindness First 28:50 Mom's Joy in Affordable ScreeningsSee omnystudio.com/listener for privacy information.

Stomach cancer is the fifth most common cancer worldwide. The impact of stomach cancer is disproportionate in South Texas, where Hispanic populations face higher incidence and earlier onset. Stomach cancer is difficult to detect early, when it's most treatable.

This editorially independent content is sponsored by Astellas.Carolyn Majcher, OD, FAAO, FORS, Director, Residency Programs and a professor at Oklahoma College of Optometry, notes how the conversation about geographic atrophy has changed with the introduction of complement inhibitor therapies. As most primary care optometrists have access to OCT technology, the opportunity to detect and potentially start treatments creates the opportunity to preserve vision for more patients. 

Is your body screaming for help? Would you know if you're ignoring life-threatening symptoms? Well, my guest today, Marisa Peters, is a passionate advocate for cancer awareness. She shares how the hustle and bustle of life can mask serious health signs, and why it's critical to listen to our bodies.  Marisa moved from a high-powered career as a Chief People Officer in the tech and entertainment industries to a late-stage rectal cancer diagnosis at 39. Marisa is now on a mission to raise awareness about colorectal cancer and empower others to take their health seriously. She's using her experience to educate and inspire, starting conversations that have been long overdue. If you're brushing off symptoms, thinking they're just part of life, this episode will inspire you to advocate for yourself and take action. You'll learn how to recognize the symptoms of colorectal cancer, why early screening is vital, and how one simple conversation can save lives.  "Be seen, get screened, use your voice, and be your biggest advocate 'cause you know your body best.. " ~ Marisa Peters In This Episode: - Meet Marisa Peters - Marisa's journey from a corporate career to cancer survivor - The diagnosis and how it changed everything - Her shift in perspective after receiving the cancer diagnosis  - Fighting for normalcy while battling cancer - Marisa's lessons on time, family, and self-care  - The importance of being seen and speaking up about health - When should healthy people get colorectal cancer screening? - How to get involved and help spread the word About Marisa Peters: Marisa Peters is a producer, speaker, and author -- living today as a young-onset rectal cancer survivor. As a former Broadway vocalist and national anthem singer for major league sports, Marisa pivoted to the corporate stage, serving as a Chief People Officer inside entertainment and tech companies.  Host of the podcast, From Carpools To Chemo, Marisa is using her voice in a new way by advocating for people to “Be Seen.” Her family launched the BE SEEN Foundation, which is on a mission to eradicate death by young-onset colorectal cancer after her successful treatment at UCLA Health.  Instagram: https://www.instagram.com/beseen.care/                    https://www.instagram.com/fromcarpoolstochemo/  Facebook: https://www.facebook.com/BeSeenBuzz  Website: www.beseen.care  Podcast: www.beseen.care/podcast            Where to find me: IG: https://www.instagram.com/jen_gottlieb/    TikTok: https://www.tiktok.com/@jen_gottlieb     Facebook: https://www.facebook.com/Jenleahgottlieb    Website: https://jengottlieb.com/    My business: https://www.superconnectormedia.com/     YouTube: https://www.youtube.com/@jen_gottlieb

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In the final part of this 3-part series, Dr Terris discussed how the early diagnosis of bladder cancer presents a significant challenge, particularly in female patients, who are frequently diagnosed at a later stage of the disease and subsequently respond less favorably to treatment modalities. A crucial component of early detection is the rigorous evaluation of hematuria, she emphasized. Microhematuria is defined strictly by microscopy. Reliance solely on a dipstick test is insufficient; any positive dipstick result necessitates a microscopic examination, she explained. Furthermore, patients currently receiving anticoagulation therapy do not bypass the standard workup, she noted. If hematuria is identified alongside a urinary tract infection or gynecological issue, the urine should be rechecked once the co-existing problem has cleared, she advised. Risk assessment must consider both common and less-recognized factors, particularly in women, according to Terris. Standard risks include exposure to cyclophosphamide or ifosfamide, Lynch syndrome, chronic indwelling Foley catheters, benzene/aromatic amine exposure, and smoking, she added. However, uro-oncologists must actively assess female patients for occupational exposures not traditionally associated with bladder cancer, she said. Patients presenting with microhematuria should be stratified into low-, intermediate-, or high-risk groups, Terris continued. The gold standard evaluation for high-risk patients is a cystoscopy and CT urogram, she reported. The CT urogram involves cross-sectional imaging of the abdomen and pelvis with and without contrast, incorporating delayed images to optimally visualize the renal pelvis and ureters for potential filling defects, she noted. If patients cannot tolerate contrast, an MR urogram is the primary alternative, she stated. If neither CT nor MR urogram can be performed, the default workup is non-contrast CT combined with cystoscopy and retrograde pyelograms, although this requires general anesthesia, she explained. Given that women are often diagnosed with bladder cancer late and face poor outcomes with advanced disease, maintaining a heightened awareness and low threshold for investigation is critical, Terris concluded.

Send us a textWhole body MRI is changing prevention from a guess into something you can actually see. Dr. Kevin White talks with Dr. Dan Durand, Johns Hopkins trained radiologist and Chief Medical Officer at Prenuvo, about how full body scans are catching silent problems early: from fatty liver and visceral fat to aneurysms, early cancers, and brain changes linked to cognitive decline and dementia. They unpack how Prenuvo's model pairs deep imaging, multiomic data, and real conversations with clinicians so patients do not just get a data dump, but a clear plan for what to do next.“Think of a whole body MRI as a home inspection for your health: you want to find the hidden leaks before the ceiling caves in.” – Dr. Dan DurandYou'll hear: • Why traditional screening only looks at a few organs and what whole body MRI adds • How often Prenuvo finds serious issues early and what that means for real people • The link between visceral fat, brain volume, and long term cognitive health • How AI is being used to measure brain regions, muscle, and fat with precision • Why reassurance from a clean scan can be just as powerful as a life saving catch • How to think about timing, HSA dollars, and making this part of your prevention planLearn more about Prenuvo and their whole body MRI at prenuvo.com.

Veonet Ireland has announced the introduction of DR.NOON AI Software by HeartEye Diagnostics - an AI-powered retinal screening system capable of detecting early signs of cardiovascular and diabetic vascular risk from a single, non-invasive eye retinal scan. At a time of high waiting lists for ophthalmology and cardiology, at 53,000 and 45,000 patients respectfully, DR.NOON offers a powerful preventive tool that can identify risk before symptoms appear. Built on clinically validated deep learning algorithms, DR.NOON AI software analyses subtle vascular patterns in the retina to uncover early indications of systemic disease, including hypertension, atherosclerosis, and microvascular changes associated with diabetes. Retinal screening to detect eye disease It delivers instant, AI-driven reports that match the outperform traditional methods in five-year cardiovascular risk prediction. This will include actionable insights for patients, identifying key risk indicators with personalised recommendations for lifestyle modification and disease management. With World Diabetes Day approaching on 14 November, the timing could not be more relevant. Diabetes remains a leading cause of vision loss among working-age adults, yet early detection can prevent over 90% of diabetes-related blindness, as it enables faster referral, timely treatment, and improved long-term outcomes for patients. Regular visits to your optometrist and enrolling in the Diabetic Retinal Screening Programme are as important as attending your diabetic clinic appointments. This is due to the increased risk of glaucoma, cataract and diabetic eye disease as a result of a diabetes diagnosis. "Diabetes, heart disease and vision loss are deeply interconnected, yet often diagnosed too late," explains Dr. Farah Ibrahim, Consultant Ophthalmologist at Veonet Ireland. "DR.NOON AI software changes that landscape - predicting cardiovascular risk for patients through a simple eye scan. This is preventive care in action: faster insights, earlier intervention, and ultimately, fewer patients joining already overstretched waiting lists." To mark its Irish debut, DR.NOON will be showcased at Veonet Ireland's upcoming CPD-accredited event, The Future of Vision: Emerging Advancements in Diabetic Eye Disease, taking place in Cork this Thursday, 13 November. The session will bring together optometrists, nurses, pharmacists and ophthalmic technicians to explore developments in diabetes eye management & experience how AI-driven innovation can reshape multidisciplinary diabetic eye care. You can learn more about the event, and reserve your spot in person or online, here. About Veonet Ireland Part of Veonet, Europe's leading ophthalmology group, Veonet Ireland is dedicated to delivering world-class, affordable, and accessible specialist eye care across Ireland. Founded by renowned ophthalmologists who recognised the value of sharing expertise, networking, and best practices, Veonet continues to advance the quality of ophthalmic care for patients across Europe. Veonet Ireland provides a supportive and positive environment where specialists and staff can grow both personally and professionally. Being a clinically led organisation, it empowers ophthalmologists to shape services and procedures in line with the highest clinical standards. See more breaking stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, Linke...

Only about one in six lung cancer cases nationwide are caught early enough for curative treatment. In Hampton Roads, health advocates say it's time to widen screening guidelines.

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Dr. Yashbir Singh talks with Dr. Bonnie Joe about her journey from engineering to breast imaging and how a systematic, analytical approach shapes her clinical practice. Dr. Joe shares insights on breast screening guidelines, dense breast management, health equity, and how AI could help close gaps in access to care. Radiology: Imaging Cancer R&E Foundation

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Download the transcript here

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Listen to the podcast here

Send us a textSeason 3 Episode 11Professor Chris Booth MBBS, FRCS – Consultant UrologistIn today's episode, we're joined by Professor Chris Booth, MBBS, FRCS — a leading Consultant Urologist and one of the UK's most respected voices in men's health. Professor Booth is the founder of CHAPS, a dedicated men's health charity established to improve awareness, early diagnosis, and access to better health services for men across the country.With a distinguished career in urology, Professor Booth has become a national expert in urological service redesign, championing modern, integrated care pathways that deliver faster, more effective, and more affordable treatment. His work is especially transformative in rural communities, where access to specialist services can be limited, and where his innovative approach has helped bridge the gap between primary and specialist care.Driven by a passion for prevention, early detection, and patient-focused care, Professor Booth continues to lead the conversation about how we can improve men's health outcomes and reduce avoidable deaths from diseases such as prostate cancer.We're thrilled to have him with us today to share his insights, experience, and vision for the future of men's health.https://chaps-uk.org#HeartTransplant#eatingdisorder#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#Harryhill#Aid's#MynaraCheck out our website at www.whostomanddick.comCheck out our website at www.whostomanddick.comCheck out our website at www.whostomanddick.com

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

When it comes to serious illness, early detection can be the difference between a difficult battle and a manageable path forward. But what if advanced diagnostics didn't require a referral, radiation, or even a reason to feel sick? In this episode of Med Tech Gurus, we sit down with Mike Wernli, Chief Operating Officer at Craft Health, to explore how they're flipping the script on traditional healthcare. With AI-enhanced full-body MRI scans, Craft Health is delivering hospital-grade insights in under 30 minutes—without contrast or complexity. But the technology is only part of the story. Mike opens up about the mindset shift required to empower patients to take control of their health before symptoms appear. He shares how Craft is combining clinical excellence with retail-like access, building a culture that thrives on purpose, and engaging communities in ways that truly matter. Whether you're an innovator in preventive care, a startup leader navigating consumer health, or someone passionate about shifting care upstream—this conversation offers both inspiration and a playbook.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University.  In part 1 of this 3-part series, Dr Terris discussed the prevalence of bladder cancer in women, as well as reasons for diagnostic disparities that contribute to poor treatment outcomes. She noted that this disease is often diagnosed at later stages in women than in men, often resulting in diagnoses of more advanced disease and translating to poorer outcomes. She added that although female patients represent a minority of those with urothelial carcinoma, retrospective data indicate that women tend to be diagnosed at later stages and consequently experience worse survival rates, regardless of the disease stage. Dr Terris identified several theories explaining why this diagnosis delay occurs. One possible reason is patient-related: women may be less likely than men to consult a physician when they notice blood in their urine because they may be conditioned to dismiss blood if they experience menstrual bleeding. However, physician behavior and bias also contribute to diagnostic disparities, Terris said. Women with suspected hematuria typically receive fewer imaging tests, she continued. Additionally, physicians may be biased, attributing hematuria to uterine bleeding, menstruation, or other benign causes.  Overall, Terris emphasized that early detection is key. If there is any suspicion of a malignancy, patients should be referred directly to a urologist, she stated. Urologists should be willing to work up cases that might ultimately be recurrent urinary tract infections or radiation cystitis to avoid undiagnosed cases of bladder cancer in women, she concluded.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guest: Jennifer Kistler, Breast Cancer Survivor & Healthcare ProfessionalHost: Jamie PrestonTopic: The importance of early detection and the emotional resilience of surviving breast cancerDiscussion Highlights:Life before diagnosis and how unexpected the news wasThe moment she heard the words, “You have breast cancer”Building a strong core of support during treatmentFinding friendship and purpose through shared experienceThe symbolism of ringing the bell and what it truly meansHow her perspective on health and strength has evolvedWhy every woman — even those without symptoms or family history — must prioritize screening www.YourHealth.Org

Is 2025 a pivotal inflection point for AI in health care? Dr. Connie Lehman, Co-Founder of Clairity, thinks so, and she has strong cause for optimism. Her organization's software-as-a-medical-device product, Clairity Breast, recently received authorization from the Food and Drug Administration as the first AI platform that predicts a woman's five-year risk of developing breast cancer.On this episode, Dr. Lehman shares her journey with Clairity, from the paper she read as a medical student that sparked the idea, to her experience navigating the new domain of image-based risk assessment with the FDA. Her current focus is on implementing the technology through education and advocacy.Dr. Lehman is passionate about advancing medicine toward risk assessment and disease prevention. Understanding risk empowers patients and their health care providers to choose the best path. Dr. Lehman envisions a future where image-based risk information is accessible and available to improve health outcomes for all.

In this special live episode of the SHE MD Podcast, Olivia Munn joins Dr. Thaïs Aliabadi, Mary Alice Haney, Dr. Shari Goldfarb, and Kristen Dahlgren, for a powerful Breast Cancer Awareness Month panel in New York City. The event coincided with NBC's Today Show coverage and the lighting of the Empire State Building in pink — marking the launch of a national conversation around early detection, AI, and prevention.Together, they explore how lifetime risk assessments, dense breast screening, and AI mammogram prediction tools like Clarity Breast are transforming breast health. The panel also discusses cancer vaccine research, genetic testing, and the importance of women knowing their individual risk scores.Listeners will hear Olivia's personal story of early detection after a high-risk score prompted further imaging, leading to her diagnosis and recovery. This episode offers clarity, action, and hope — empowering every listener to become their own health advocate and partner with their medical team.Subscribe to SHE MD Podcast for expert tips on PCOS, Endometriosis, fertility, and hormonal balance. Share with friends and visit the SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.What You'll LearnHow lifetime risk assessment tools can identify breast cancer risk before symptoms appearWhy dense breast tissue requires supplemental screening beyond mammogramsHow AI predictive tools like Clarity Breast are revolutionizing early detectionThe promise of vaccine research and genetic testing in future breast cancer preventionKey Timestamps(00:00) Live event intro and Breast Cancer Awareness Month context(03:30) Olivia's story: risk score, MRI findings, and early diagnosis(13:00) Dr. Aliabadi and Dr. Goldfarb on dense breast screening and AI tools(16:00) Cancer vaccine and immunotherapy discussion with Kristen Dahlgren(27:00) Genetic testing and family history: understanding your risk(34:00) Audience Q&A: emotional recovery and advocacy(42:00) Is there support for young women being diagnosed with breast cancer?(51:30) Clarifying the term Risk AssessmentKey TakeawaysEvery woman should know her lifetime breast cancer risk scoreDense breasts may obscure cancers — MRI and ultrasound can save livesAI mammogram tools are changing detection from reactive to predictiveResearch into cancer vaccines offers hope for prevention and recurrence reductionAdvocacy and awareness remain key — early action leads to better outcomesGuest BiosOlivia MunnOlivia Munn is an actress, health advocate, and breast cancer survivor. After receiving a high lifetime risk assessment score, she underwent further imaging that revealed cancer across multiple quadrants, leading to a bilateral mastectomy. Since publicly sharing her diagnosis in 2024, she has dedicated her platform toward raising awareness about early detection, risk assessment, and empowering women with knowledge about their breast health.Dr. Shari Goldfarb, MDDr. Shari Goldfarb is a breast medical oncologist at Memorial Sloan Kettering, with a clinical focus on early and advanced breast cancer. Her research centers on survivorship, symptom management, fertility, sexual health, and quality of life for breast cancer patients. She participates in clinical trials aimed at improving outcomes for women during and after treatment.Kristen DahlgrenKristen Dahlgren is a former NBC correspondent who, after her own stage 2 breast cancer diagnosis, left journalism to found the Cancer Vaccine Coalition. She collaborates with top cancer centers to accelerate immunotherapy and vaccine development in breast cancer and advocates for preventive strategies beyond current standards.LinksOlivia Munn – https://www.instagram.com/oliviamunnDr. Shari Goldfarb – https://www.mskcc.org/profile/shari-goldfarbKristen Dahlgren – https://www.linkedin.com/in/kristen-dahlgren-886519292/Donna McKay – https://www.bcrf.org/teamResources MentionedBreast Cancer Research Foundation (BCRF) – Funding for innovative breast cancer research and prevention programs

In this episode of Longevity by Design, host Gil Blander sits down with Florence Comite, MD, physician-scientist and founder of the Comite Center for Precision Medicine & Healthy Longevity. They explore why a one-size-fits-all approach to longevity falls short and how personalized data, from biomarkers to genetics, can spot early signs of disease before symptoms appear.Florence explains her “Nof1” method, which uses deep testing, wearables, and personal history to craft precise health plans. She highlights how sleep, more than exercise or diet, shapes long-term health but remains hard for most people to optimize. Using real-world examples, Florence shows why tracking markers like insulin and hormones matter, and why most people need support to turn health knowledge into action.The conversation covers the limits of standard medical care, the value of knowing your family history, and how even the best routines must adapt over time. Florence urges listeners to get curious about their own data and take steps—however small—toward better health.Guest-at-a-Glance 

This life-saving conversation is for anyone who has—or loves someone who has—breasts. It's what to look for, what to ask, what screenings you *actually need* (not just what is offered), and every decision point you have (even if it's not offered to you) if you are facing surgery.   This Breast Cancer Awareness Month, Glennon, Abby, and Amanda empower us with the most vital tool we have: information. Amanda reflects on how self-advocacy led her to her own breast cancer diagnosis—and we hear from the pod squad about how Amanda's transparency helped save their lives. Then, we're joined by Amanda's renowned doctor, Dr. Lucy M. De La Cruz, who reminds us that every patient has agency—and shares how to choose the treatment path that's right for you. And special shout out and thanks to Pod Squader Lori Mihalich-Levin (@mindfulreturn) for being such a special part of this story! If you or someone you love has been diagnosed with breast cancer, please save this episode or send it to the people you love. We love you.  For more on Amanda's Breast Cancer journey:  - Amanda's Diagnosis and What's Next (Part 1) - Amanda's Diagnosis and What's Next (Part 2) - Amanda Returns Post Surgery: Here's What She Wants You to Know  - What Amanda's Learned About Life, Love & Community (Post Surgery Pt 2)  - Early Detection, Mammograms & Breast Cancer Care with Dr. Rachel Brem  - Expert Advice on Genetic Testing, Cancer Prevention & Care Disparities with Dr. Rachel Brem  About Dr. De La Cruz:  Dr. Lucy M. De La Cruz is an internationally recognized breast surgical oncologist and the youngest Latina Chief of Breast Surgery in an academic institution in the United States. She serves as Chief of Breast Surgery and Director of the Betty Lou Ourisman Breast Health Center at MedStar Georgetown University Hospital, a nationally ranked center of excellence in breast cancer care. Dr. De La Cruz specializes in nipple-sparing mastectomies with structural preservation and resensation, with a focus on highly specialized single-stage implant reconstruction. Patients describe her not only as a world-class surgeon, but as a fierce advocate and mentor—especially for women navigating the complexities of diagnosis, treatment, and survivorship. 

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode is sponsored by IDEXX This podcast episode, hosted by Adam Christman, DVM, MBA, features oncologists Dana Connell, DVM, MPH, DACVIM (Oncology) and Zachary L. Neumann, DVM, MS, DACVIM (Oncology), discussing the significance of early cancer detection in dogs. The conversation focuses on the IDEXX Cancer Dx testing. The doctors explain how the test, which can be included in routine wellness exams, provides rapid results, enabling veterinarians to make timely diagnoses and improve treatment outcomes. They also touch on the importance of the veterinary team in communicating sensitive news to pet owners and the future potential of the test to screen for other types of cancer.

October means it's time to talk boob health!

In this episode, David Harding, Senior Vice President of Pipeline Product Management at Exact Sciences, discusses a new survey of healthcare executives on multi-cancer early detection. He shares insights on system readiness, patient demand, and the barriers health systems face in adopting this transformative approach to cancer screening.This episode is sponsored by Exact Sciences.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.